Journal of Oncology / 2020 / Article / Tab 5

Research Article

Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Table 5

Overall and progression-free survival according to first-line chemotherapy regimen in the overall population and the group of patients diagnosed during study enrolment.

Overall populationDiagnosed during enrolment
Median95% CI valueMedian95% CI value

OS (months)
Nab-paclitaxel-gemcitabine14.110.6–17.60.42912.38.8–15.90.125
FOLFIRINOX/CAPOXIRI11.17.7–14.69.96.4–13.5
Gemcitabine10.43.0–17.76.10–14.8
Other regimens17.16.6–27.613.23.4–23.0

PFS (months)
Nab-paclitaxel-gemcitabine7.66.2–9.00.0046.76.0–7.30.001
FOLFIRINOX/CAPOXIRI6.94.1–9.76.34.6–8.0
Gemcitabine2.92.7–3.02.92.5–3.2
Other regimens7.03.2–10.85.31.2–9.4

CAPOXIRI, oxaliplatin/irinotecan/capecitabine; 95% CI, 95% confidence intervals; FOLFIRINOX, oxaliplatin/irinotecan/leucovorin/5-fluorouracil; OS, overall survival; PFS, progression-free survival.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.